Assessment of linezolid-induced thrombocytopenia in older patients: reflections from a palliative care unit
Öz
Purpose: Linezolid (LZD) is an antibiotic which is effective against resistant gram-positive bacteria. The aim of this study was to investigate the characteristics and risk factors of linezolid-induced thrombocytopenia (LIT).
Materials and Methods: This monocentric and retrospective study comprised 93 older patients treated with LZD for a minimum of seven days in a palliative care unit. Thrombocytopenia was defined as a decrease in platelet count below 150x103/mm3 or a ≥ 50% decrease. Complete blood count (CBC) and biochemical analyses were performed on the first, third, seventh, last day of treatment and after treatment.
Results: The mean age of the patients was 73.7 years (±7.9 years). Thrombocytopenia was observed in 48 patients. The mean age, median duration of hospitalisation and LZD treatment were higher, and baseline serum albumin concentration and calcium level were lower in patients with LIT. In the groups aged ≥75 years, with albumin levels <25 g/L and platelet counts <200x103/mm, LIT was more frequent. Repeated measures ANOVA analysis was conducted, which revealed a significant interaction effect between platelet counts and the duration of exposure. Multivariate logistic regression analysis identified female gender, age ≥75 years, LZD treatment duration >14 days, serum baseline albumin <25g/L and platelet count <200x103/mm3 as risk factors for LIT.
Conclusion: Older patients receiving LZD treatment in a palliative care unit with risk factors should be closely monitored hematological. CBC should be performed once in the first week, and 14th day of treatment to prevent thrombocytopenic complications.
Anahtar Kelimeler
Kaynakça
- Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis. 2003;36:473-81.
- Wu VC, Wang YT, Wang CY, Tsai IJ, Wu KD, Hwang JJ et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis. 2006;42:66-72.
- Senneville E, Legout L, Valette M, Yazdanpanah Y, Beltrand E, Caillaux M et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther. 2006;28:1155-63.
- Douros A, Grabowski K, Stahlmann R. Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones. Expert Opin Drug Metab Toxicol. 2015;11:1849-59.
- Baik SH, Choi YK, Kim HS, Yoon YK, Sohn JW, Kim MJ. A probable case of syndrome of inappropriate antidiuretic hormone secretion associated with linezolid. Am J Health Syst Pharm. 2015;72:1865-9.
- Talaie H, Hosseini SM, Nazari M, Esfahani MS, Barari B. Risk factors of hospital-acquired thrombocytopenia in toxicological intensive care unit. International Journal of Medical Toxicology and Forensic Medicine. 2020;10:32256
- Bernstein WB, Trotta RF, Rector JT, Tjaden JA, Barile AJ. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother. 2003;37:517-20.
- Hanai Y, Matsuo K, Ogawa M, Higashi A, Kimura I, Hirayama S et al. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia. J Infect Chemother. 2016;22:536-42.
- Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002;46:2723-6.
- Moraza L, Leache L, Aquerreta I, Ortega A. Linezolid-induced haematological toxicity. Farm Hosp. 2015;39:320-6.
